Ambrx, China Everbright, Hopu Investment Management, Shanghai Fosun Pharmaceutical, WuXi PharmaTech deal

China Everbright’s health care fund, Fosun, Hopu and WuXi will acquire Ambrx for an undisclosed amount. The consortium of buyers expects the transaction to close this quarter but did not respond to inquiries for additional details in time for publication. Ambrx declined to provide details. ...